Zogenix plans public offering of 12 million shares

Earlier on Wednesday, drugmaker Zogenix Inc. announced that it plans to sell all its shares in a public offering of 12 million from the common stock.

The underwriters are presented with an opportunity to purchase supplementary shares amounting to 1.8 million.
With corporate offices in San Diego and Emeryville, Calif., Zogenix sells Sumavel DosePro needle-free delivery system for the treatment of acute migraine and cluster headaches.

In the quarter that ended on June 30, the company lost $19.2 million, or 56 cents per share, which is comparable with losses of $27.8 million in the previous year.